INT25334

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 1986
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 16
Total Number 16
Disease Relevance 9.01
Pain Relevance 4.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Pla2g2a) extracellular space (Pla2g2a) endoplasmic reticulum (Pla2g2a)
Anatomy Link Frequency
blood 1
uterine 1
Pla2g2a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cINOD 6 99.28 Very High Very High Very High
Inflammation 91 99.08 Very High Very High Very High
Paracetamol 3 99.00 Very High Very High Very High
Hyperalgesia 8 98.48 Very High Very High Very High
dexamethasone 47 98.36 Very High Very High Very High
Dismenorea 5 98.20 Very High Very High Very High
Dopamine 1 94.32 High High
halothane 10 89.92 High High
cytokine 19 89.80 High High
anesthesia 5 89.12 High High
Disease Link Frequency Relevance Heat
Granuloma 2 100.00 Very High Very High Very High
Obstructive Jaundice 48 99.72 Very High Very High Very High
Injury 45 99.72 Very High Very High Very High
Pancreatitis 91 99.62 Very High Very High Very High
INFLAMMATION 115 99.58 Very High Very High Very High
Hyperalgesia 12 98.48 Very High Very High Very High
Inflammatory Bowel Disease 6 98.48 Very High Very High Very High
Colitis 6 98.20 Very High Very High Very High
Dysmenorrhea 5 98.20 Very High Very High Very High
Sciatic Neuropathy 2 96.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This increase in FAME (45%) was inhibited by mepacrine (quinacrine) (10 microM), an inhibitor of PLA2.
Negative_regulation (inhibitor) of PLA2
1) Confidence 0.56 Published 1999 Journal J Ocul Pharmacol Ther Section Abstract Doc Link 10229494 Disease Relevance 0 Pain Relevance 0.54
At Day 14, PLA2 activity was reduced in the chymopapain- (47.8 +/- 12.3) and betamethasone- (39.7 +/- 9.5) treated groups compared with the saline control group (62.3 +/- 11.2), (saline- vs. chymopapain-treated groups p < 0.05; saline- vs. betamethasone-treated groups p < 0.01).
Negative_regulation (reduced) of PLA2
2) Confidence 0.54 Published 1997 Journal J. Neurosurg. Section Abstract Doc Link 9171179 Disease Relevance 0.60 Pain Relevance 0.55
These data indicate that chymopapain exhibits antiinflammatory properties in vivo, reducing PLA2 activity and ameliorating mechanical hyperalgesia in this model of inflammatory sciatic neuropathy.
Negative_regulation (reducing) of PLA2 associated with hyperalgesia, inflammation and sciatic neuropathy
3) Confidence 0.54 Published 1997 Journal J. Neurosurg. Section Abstract Doc Link 9171179 Disease Relevance 0.90 Pain Relevance 0.50
Local administration of anti-inflammatory drugs such as dexamethasone, indomethacin, or a PLA2 inhibitor such as p-bromophenacyl bromide significantly inhibited exudate volume, cellular influx, granuloma formation, exudate PGE2 levels and PLA2 activity, to varying degrees.
Negative_regulation (inhibited) of PLA2 associated with inflammation, cinod, granuloma and dexamethasone
4) Confidence 0.53 Published 1993 Journal Int. J. Immunopharmacol. Section Abstract Doc Link 8375942 Disease Relevance 0.54 Pain Relevance 0.36
Pharmacologic inhibition of PLA2G6, but not PLA2G2A, attenuated PCB-induced stimulation of gd20 uterine contractions (P < 0.05).
Negative_regulation (inhibition) of PLA2G2A in uterine associated with dismenorea
5) Confidence 0.42 Published 2006 Journal Biol. Reprod. Section Abstract Doc Link 16436530 Disease Relevance 0.28 Pain Relevance 0.28
Dexamethasone treatment significantly reduced all parameters determined, whereas p-bromophenacyl bromide had a significant inhibitory effect on PLA2 activity and PGE2 release, and indomethacin only restored PGE2 levels.
Negative_regulation (effect) of PLA2 associated with dexamethasone
6) Confidence 0.39 Published 1993 Journal Int. J. Immunopharmacol. Section Abstract Doc Link 8375942 Disease Relevance 0.49 Pain Relevance 0.34
Accordingly, it has been postulated that control of lipid mediator production by inhibition of PLA2 would be useful for the treatment of IBD.
Negative_regulation (inhibition) of PLA2 associated with inflammatory bowel disease
7) Confidence 0.30 Published 2003 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 12724134 Disease Relevance 0.56 Pain Relevance 0.11
closely related with SAP severity, and the PLA2 inhibitor can improve the
Negative_regulation (inhibitor) of PLA2 associated with pancreatitis
8) Confidence 0.27 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2234334 Disease Relevance 1.50 Pain Relevance 0.48
The present study supports the concept that inclusive control of lipid mediator production by PLA2 inhibition is a plausible approach to the treatment of colitis and introduces the ExPLIs as a prototype of a novel NSAID for the treatment of intestinal inflammation.
Negative_regulation (inhibition) of PLA2 associated with colitis, inflammation and cinod
9) Confidence 0.22 Published 2003 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 12724134 Disease Relevance 0.71 Pain Relevance 0.26
To sum up, Salvia miltiorrhizae injection can exert protective effects on the spleen and thymus of SAP rats and the spleen of OJ rats through reducing the contents of endotoxin and PLA2 in blood, improving the pathological damage present in the spleen and thymus of SAP rats and the spleen of OJ rats, and inhibiting the expression of Bax protein in the spleen of OJ rats and the apoptosis.
Negative_regulation (reducing) of PLA2 in blood associated with pancreatitis, apoptosis and obstructive jaundice
10) Confidence 0.21 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2790077 Disease Relevance 1.62 Pain Relevance 0.09
Several recent reports have shown that quinacrine, besides being a potent inhibitor of PLA2, suppresses the generation of ODFR.
Negative_regulation (inhibitor) of PLA2
11) Confidence 0.16 Published 1996 Journal Transplantation Section Abstract Doc Link 8781605 Disease Relevance 0.31 Pain Relevance 0
Glucocorticoids inhibit phospholipase A2 (PLA2) by inducing in the target cells the synthesis of inhibitory proteins, the lipocortins, and consequently reduce the release of eicosanoids in a number of cells and tissues.
Negative_regulation (inhibit) of PLA2
12) Confidence 0.10 Published 1986 Journal Agents Actions Section Abstract Doc Link 3532720 Disease Relevance 0.10 Pain Relevance 0.14
Inhibitors of PLA2, cyclooxygenase and thromboxane synthetase injected i.p. 7 h after paracetamol prevented hepatotoxicity as measured by SGPT activity but did not prevent an increase in glycogen phosphorylase "a" activity.
Negative_regulation (Inhibitors) of PLA2 associated with paracetamol and hepatotoxicity
13) Confidence 0.06 Published 1989 Journal Eicosanoids Section Abstract Doc Link 2516744 Disease Relevance 0.43 Pain Relevance 0.27
Thus, it can also inhibit phospholipase A2 (PLA2) [24].
Negative_regulation (inhibit) of PLA2
14) Confidence 0.02 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC548144 Disease Relevance 0 Pain Relevance 0.04
Inhibition of phospholipase A2 (PLA2), the enzyme that liberates arachidonic acid from membrane phospholipids, provides limited protection in stroke because the metabolism of polyunsaturated fatty acids (PUFA) is required to generate several anti-inflammatory eicosanoids [46] and epoxides [47].
Negative_regulation (Inhibition) of PLA2 associated with inflammation and stroke
15) Confidence 0.01 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 0.75 Pain Relevance 0.19
These effects were highly specific for the purinergic system since in the same cells inhibition of PLA2 had no effect on astrocytic elongation induced by classical growth factors such as bFGF [47].
Negative_regulation (inhibition) of PLA2
16) Confidence 0.01 Published 2006 Journal Purinergic Signal Section Body Doc Link PMC2096663 Disease Relevance 0.21 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox